pharma · SH2B1 Deficiency Obesity · Prader-Willi Syndrome · SLNO
SOLENO THERAPEUTICS
SOLENO THERAPEUTICS INC
Soleno Therapeutics is a pharma organization headquartered in Redwood City, USA. It trades on NYSE under ticker SLNO. Primary therapeutic focus areas include SH2B1 Deficiency Obesity, Prader-Willi Syndrome. NovaPharmaNew
Redwood City, USA HQ
199 Employees
Public company Type
SLNO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Employees
- 199
- Programs
- 2
- Drugs
- 4
- Patents
- 0
DCCR (diazoxide choline) extended-release tablets
Phase 2 · small molecule · SH2B1 Deficiency Obesity
DCCR (diazoxide choline) extended-release tablets for SH2B1 Deficiency Obesity is a Phase 2 program (small_molecule) at SOLENO THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Internal code C615
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- SOLENO THERAPEUTICS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- SH2B1 Deficiency Obesity
- Status
- active
- Trials
- 1